or Try an Advanced Search...

    Chimeric Antigen Receptor T Cell Stocks List

    Symbol Grade Name % Change
    GDTC C CytoMed Therapeutics Limited -0.47
    JANX C Janux Therapeutics, Inc. -5.13
    PSTX D Poseida Therapeutics, Inc. -0.18
    CRBU D Caribou Biosciences, Inc. 1.02
    TSVT F 2seventy bio, Inc. 0.64
    SNTI F Senti Biosciences, Inc. 1.88
    CARM F Carisma Therapeutics, Inc. -3.07
    NKTX F Nkarta, Inc. -2.00
    NTLA F Intellia Therapeutics, Inc. 7.04
    ACET F Adicet Bio, Inc. -2.31
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Medicine Immune System Biopharmaceutical Biotechnology Cancer Chimeric Antigen Receptor Clinical Medicine Solid Tumors Antigen Biology Cancer Immunotherapy Cancer Treatment Cell Therapy Life Sciences Natural Killer Cell Breakthrough Therapy CD19 Disease Emerging Technologies Gene Therapy

    Related ETFs - A few ETFs which own one or more of the above listed Chimeric Antigen Receptor T Cell stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 4.96
    GNOM F Global X Genomics & Biotechnology ETF 4.5
    ARKG F ARK Genomic Revolution Multi-Sector ETF 3.89
    CANC D Tema Oncology ETF 3.01
    ARKK B ARK Innovation ETF 2.09
    View all Chimeric Antigen Receptor T Cell ETFs...
    Compare ETFs
    Compare CNCR to ARKK Compare GNOM to ARKG Compare GNOM to ARKK

        Chimeric Antigen Receptor T Cell Stocks Recent News

        Date Stock Title
        Nov 20 CRBU Caribou Biosciences to Participate in Upcoming Investor Conferences
        Nov 20 GDTC Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
        Nov 19 NTLA Intellia Therapeutics Announces Promising CRISPR Therapy Results
        Nov 19 NTLA ReCode to secure funds for cystic fibrosis gene correction treatments
        Nov 19 NTLA Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
        Nov 19 JANX Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation
        Nov 19 NTLA Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
        Nov 18 ACET Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
        Nov 18 NTLA Intellia’s gene editing therapy shows early potential in rare heart condition
        Nov 18 ACET Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
        Nov 18 NTLA CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
        Nov 18 ACET Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?
        Nov 17 CARM Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
        Nov 16 NTLA Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
        Nov 16 ACET Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
        Nov 16 JANX Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors
        Nov 15 TSVT US$8.25: That's What Analysts Think 2seventy bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest Results
        Nov 15 SNTI Senti Biosciences GAAP EPS of -$6.31
        Nov 14 SNTI Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights
        Related Industries: Biotechnology
        Related Stock Lists: Medicine Immune System Biopharmaceutical Biotechnology Cancer Chimeric Antigen Receptor Clinical Medicine Solid Tumors Antigen Biology Cancer Immunotherapy Cancer Treatment Cell Therapy Life Sciences Natural Killer Cell Breakthrough Therapy CD19 Disease Emerging Technologies Gene Therapy
        Chimeric Antigen Receptor T Cell

        Chimeric Antigen Receptor T Cell (CAR-T) is a type of immunotherapy that uses a patient’s own T cells to fight cancer. The T cells are genetically modified to express a special receptor, called a chimeric antigen receptor (CAR), which is designed to recognize and bind to a specific protein found on the surface of cancer cells. Once the CAR-T cells bind to the cancer cells, they can kill them. CAR-T therapy has been used to treat certain types of blood cancers, such as leukemia and lymphoma, and is being studied for other types of cancer.

        Browse All Tags